INTRODUCTION
============

Although the cancer-related death rate has significantly dropped since 1991, and led to more than 1.7 million deaths by the year 2012, it is still the leading cause of death \[[@B1]\]. Gastric cancer (GC) represents the men\'s third and the women\'s forth leading cancer diagnosed and the third leading cause of death among both men and women in China \[[@B2]\]. With great progress in the diagnoses and treatments, the prognosis of GC has greatly improved, while the 5-year survival rate is still very poor in individuals with advanced GC \[[@B3]\]. Conventional biomarkers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9, have been inefficient because of their low sensitivity and specificity that can hardly predict overall survival accurately \[[@B4]\]. Therefore, novel biomarkers are needed for early diagnoses and determining accurate prognoses.

Fibrinogen and platelets play complex and varied roles in tumor formation and progression. Previous studies have reported that platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cells \[[@B5]\]. Satoshi Takagi reported that platelets can promote tumor growth and metastasis via direct interaction between aggrus/podoplanin and clec-2 \[[@B6]\]. Moreover, in our previous study, we found that serum fibrinogen levels were positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy \[[@B7]\]. Lian et al. \[[@B8]\] reported that mean platelet volume (MPV) predicted chemotherapy responses and prognoses in patients with unresectable gastric cancer. For these reasons, we conducted this study to investigate the combination of functions of fibrinogen, platelets, and MPV for predicting survival of patients with GC.

MATERIALS AND METHODS
=====================

Patient selection
-----------------

For the study, 1,946 consecutive histologically proven GC patients, aged from 19 to 88 (mean age: 62 years), that underwent gastrectomy between January 2007 and December 2011, and 299 patients with benign gastric tumor (BGT) between January 2000 and June 2018 at the Harbin Medical University Cancer Hospital (Heilongjiang, China) were recruited. All of these patients signed the informed consents for the use of their data for future study when admitted to our hospital and this research obtained the approval and support of the Medical Ethics Committee(approval number SHGC-1029) of Harbin Medical University Cancer Hospital.

The inclusion criteria of GC patients were as follows: all of these patients 1) underwent total or subtotal gastrectomy; 2) never received chemotherapy, radiotherapy, or other anticancer treatments; 3) survived for more than two months and none died in perioperative period; 4) never received transfusions or other blood products before blood examination; 5) died from GC or related diseases. BGT included gastric polyps, gastric leiomyoma, gastric neurofibroma, and others. Blood examinations were conducted immediately or the second day after being admitted to our hospital to assess platelet count (10^9^/L), fibrinogen (g/L), MPV (fL), CEA (ng/mL), and CA 19-9 (U/mL). The pathological staging was based on the 7^th^ edition of the TNM-classification (for the "Tumor-Nodes-Metastases" system) by the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC).

For our convenience, we used the following terms: fibrinogen\*MPV (FM), platelet count\*fibrinogen\*MPV (PFM), fibrinogen count/MPV ratio (FMR), platelet count\*fibrinogen (PF), (platelet count\*fibrinogen)/MPV ratio (PFMR), platelet count\*MPV (PM), platelet count/MPV ratio (PMR).

Patient follow-up
-----------------

These GC patients were followed-up every 3 months for the first 2 years and every 6 months in the following several years until death or June 2016. The follow-up time varied from 3 months to 9 years with an average duration of 37 months, and the overall survival time was evaluated from surgery to death.

Statistical analysis
--------------------

The Student\'s t-test was used to compare the levels of fibrinogen, platelets, MPV, and FMR among different stages. The optimal cut-off levels for fibrinogen, platelet, MPV, FMR, and PMR were determined by receiver operating curve (ROC) analysis \[[@B9]\]. Chi-square test was used to compare and assess the association of platelets with fibrinogen and clinicopathological characteristics. Survival curves were calculated by Kaplan-Meier survival analysis along with log-rank test. Multivariate analysis was evaluated by Cox proportional hazardous model, and all of the significant factors in the univariate analysis were used in multivariate analysis. P\<0.05 was considered statistically significant. All of the statistical analyses were performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA).

RESULTS
=======

The relationship between clinicopathological characteristics, prognosis, and biomarkers
---------------------------------------------------------------------------------------

After comparison of fibrinogen, platelet, and MPV levels at different stages, we found that the differences were significant for fibrinogen in BGT vs. GC, I vs. II, I vs. III, I vs. IV, II vs. III, and II vs. IV; platelet in BGT vs. GC, I vs. II, I vs. III, I vs. IV, and II vs. III; and MPV in BGT vs. GC, I vs. II, and I vs. IV ([Fig. 1](#F1){ref-type="fig"}). No other significant differences were observed between any other stages. In general, the levels of fibrinogen, platelets, and MPV were increased along with stages developed.

![Comparison of fibrinogen, platelet, MPV, and FMR between different stages. Data represents averages and standard deviation of plasma fibrinogen, platelet, MPV, and FMR levels in peripheral blood.\
MPV = mean platelet volume; FMR = fibrinogen to mean platelet volume ratio.\
^\*^P\<0.001; ^†^P\<0.05.](jgc-18-368-g001){#F1}

The ROC curves and cut-off points for fibrinogen, platelet, MPV, FM, PFM, FMR, PF, PFMR, PM, and PMR of GC patients are shown in [Fig. 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}. As the cut-off point for MPV was not significant, we took the upper limit of normal level 11.0 to divide MPV. Next, in univariate survival analyses, patients with low fibrinogen and platelet levels had better prognoses, but no significant differences in MPV levels were observed ([Fig. 3](#F3){ref-type="fig"}). So, we investigated the relationships between fibrinogen and platelets and clinicopathological features ([Table 2](#T2){ref-type="table"}). The patients were divided into 2 groups based on the mean age (62 years), the mean value of maximum diameter of the tumor (6.16 cm), and the mean value of MLNR (31.5%). Fibrinogen level was significantly associated with age, tumor depth (T), lymph node metastasis (N), distant metastasis (M), AJCC stage (TNM), radicality, tumor size, metastasis lymph node rate (MLNR), CA19-9, and CEA (P~all~\<0.05). Platelet level was significantly associated with sex, age, T, N, TNM, radicality, tumor size, MLNR, CA 19-9, and CEA (P~all~\<0.05), and was not significant for distant metastasis (P=0.715).

![Optimal cut-off points for these indexes were on with ROC curves.\
ROC = receiver operating curve; PFM = platelet\*fibrinogen\*mean platelet volume; PF = platelet\*fibrinogen; PM = platelet\*mean platelet volume; PMR = platelet to mean platelet volume ratio; FM = fibrinogen\*mean platelet volume; FMR = fibrinogen to mean platelet volume ratio; PFMR = (platelet\*fibrinogen) to mean platelet volume ratio; MPV = mean platelet volume.](jgc-18-368-g002){#F2}

###### The optimal cut-off point for overall survival

![](jgc-18-368-i001)

  Variables    AUC     Cut-off point   P-value
  ------------ ------- --------------- ---------
  Fibrinogen   0.612   3.75            \<0.001
  FM           0.608   29.14           \<0.001
  PFM          0.594   7,965.51        \<0.001
  FMR          0.589   0.41            \<0.001
  PF           0.586   1,057.53        \<0.001
  PFMR         0.574   117.87          \<0.001
  PM           0.541   1,722.40        0.004
  Platelet     0.538   290.50          0.007
  PMR          0.529   28.88           0.042
  MPV          0.502   \-              0.910

FM = fibrinogen\*mean platelet volume; PFM = platelet\*fibrinogen\*mean platelet volume; FMR = fibrinogen to mean platelet volume ratio; PF = platelet\*fibrinogen; PFMR = (platelet\*fibrinogen) to mean platelet volume ratio; PM = platelet\*mean platelet volume; PMR = platelet to mean platelet volume ratio; MPV = mean platelet volume; AUC = area under curve.

![Kaplan-Meier curves for overall survival based on levels of fibrinogen, platelet, and MPV.\
MPV = mean platelet volume.](jgc-18-368-g003){#F3}

###### Relationship between clinicopathological features and fibrinogen and platelets

![](jgc-18-368-i002)

  Variables            Fibrinogen level (g/L)   Platelet level (10^9^/L)                                         
  -------------------- ------------------------ -------------------------- --------- --------- ----- -- -------- ---------
  Sex                                                                      3.102     0.078              13.798   \<0.001
                       Female                   370                        141       311       200               
                       Male                     979                        456       1,002     433               
  Age (yr)                                                                 21.692    \<0.001            7.349    0.007
                       ≤62                      708                        245       615       338               
                       \>62                     641                        352       698       295               
  Tumor depth                                                              35.968    \<0.001            35.315   \<0.001
                       T1                       110                        13        103       20                
                       T2                       142                        41        141       42                
                       T3                       347                        153       352       148               
                       T4                       750                        390       717       423               
  Lymph nodes                                                              29.992    \<0.001            14.086   0.003
                       N0                       349                        103       326       126               
                       N1                       250                        84        242       92                
                       N2                       286                        153       286       153               
                       N3                       464                        257       459       262               
  Metastasis                                                               6.654     0.01               0.133    0.715
                       M0                       1,223                      518       1,177     564               
                       M1                       126                        79        136       69                
  AJCC stage                                                               46.961    \<0.001            25.595   \<0.001
                       I                        136                        23        134       25                
                       II                       360                        108       324       144               
                       III                      727                        387       719       395               
                       IV                       126                        79        136       69                
  Radicality                                                               55.321    \<0.001            9.564    0.002
                       R0                       1,062                      374       997       439               
                       R1 or R2                 287                        223       316       194               
  Tumor size (cm)                                                          60.413    \<0.001            45.91    \<0.001
                       ≤6.16                    951                        312       919       344               
                       \>6.16                   398                        285       394       289               
  MLNR^\*^                                                                 612.386   \<0.001            6.115    0.013
                       ≤31.5%                   1,035                      100       791       344               
                       \>31.5%                  314                        497       522       289               
  Differentiation^†^                                                       0.087     0.767              0.98     0.322
                       Differentiated           176                        139       205       110               
                       Undifferentiated         926                        705       1,108     523               
  CA 19-9 (U/mL)                                                           14.739    \<0.001            35.334   \<0.001
                       ≤37                      1,085                      436       1,077     444               
                       \>37                     264                        161       236       189               
  CEA (ng/mL)                                                              4.573     0.032              45.491   \<0.001
                       ≤5                       1,052                      439       1,065     426               
                       \>5                      297                        158       248       207               

AJCC = The American Joint Committee on Cancer; MLNR = metastasis lymph node rate; CA = carbohydrate antigen; CEA = carcinoembryonic antigen.

^\*^The average MLNR was 31.5%; ^†^Grades 1 and 2 were differentiated, and grades 3 and 4 were undifferentiated.

The relationship between indexes, clinicopathological characteristics, and clinical prognosis
---------------------------------------------------------------------------------------------

In the univariate survival analyses, we found that patients with low FM, PFM, FMR, PF, PFMR, PM, and PMR exhibited better prognoses and longer overall survival times (P~all~\<0.05) ([Fig. 4](#F4){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). Additionally, age, T, N, M, TNM stage, radicality, tumor size, MLNR differentiation, CA 19-9, and CEA were all associated with overall survival times. When we included age, T, N, M, TNM stage, radicality, tumor size, MLNR, differentiation, CA19-9, CEA, fibrinogen and FMR into multivariate analysis, the results showed that T, N, M, TNM stage, radicality, tumor size, MLNR, fibrinogen, and FMR were all independent risk factors affecting patient survival (P~all~\<0.05).

![Kaplan-Meier curves for overall survival based on FM, PFM, FMR, PF, PFMR, PM, and PMR.\
FM = fibrinogen\*mean platelet volume; PFM = platelet\*fibrinogen\*mean platelet volume; FMR = fibrinogen to mean platelet volume ratio; PF = platelet\*fibrinogen; PFMR = (platelet\*fibrinogen) to mean platelet volume ratio; PM = platelet\*mean platelet volume; PMR = platelet to mean platelet volume ratio.](jgc-18-368-g004){#F4}

###### Univariate and multivariate analysis of factors for overall survival

![](jgc-18-368-i003)

  Factors              Univariate K--M   Multivariate Cox       
  -------------------- ----------------- ---------------------- ---------
  Sex                  0.655                                    
  Age (yr)             0.018             1.098 (0.985--1.224)   0.091
  Tumor depth          \<0.001           1.221 (1.101--1.355)   \<0.001
  Lymph nodes          \<0.001           1.250 (1.136--1.377)   \<0.001
  Distant metastasis   \<0.001           0.665 (0.553--0.878)   0.004
  AJCC stage           \<0.001           2.088 (1.687--2.585)   \<0.001
  Radicality           \<0.001           2.096 (1.820--2.414)   \<0.001
  Tumor size (cm)      \<0.001           1.305 (1.160--1.468)   \<0.001
  MLNR                 \<0.001           1.291 (1.101--1.514)   0.002
  Differentiation      \<0.001           1.156 (0.988--1.351)   0.070
  CA 19-9 (U/mL)       0.019             0.993 (0.873--1.131)   0.919
  CEA (ng/mL)          0.002             1.125 (0.993--1.274)   0.065
  Fibrinogen           \<0.001           1.290 (1.100--1.513)   0.002
  FM                   \<0.001                                  
  PFM                  \<0.001                                  
  FMR                  \<0.001           0.842 (0.723--0.981)   0.027
  PF                   \<0.001                                  
  PFMR                 \<0.001                                  
  PM                   \<0.001                                  
  Platelet             \<0.001                                  
  PMR                  0.035                                    

HR = hazard ratio; CI = confidence interval; AJCC = The American Joint Committee on Cancer; MLNR = metastasis lymph node rate; CA = carbohydrate antigen; CEA = carcinoembryonic antigen; FM = fibrinogen\*mean platelet volume; PFM = platelet\*fibrinogen\*mean platelet volume, FMR = fibrinogen to mean platelet volume ratio; PF = platelet\*fibrinogen; PFMR = (platelet\*fibrinogen) to mean platelet volume ratio; PM = platelet\*mean platelet volume; PMR = platelet to mean platelet volume ratio.

Finally, we examined the value of these indicators for different stages ([Table 4](#T4){ref-type="table"}). Fibrinogen, FM, PFM, and PF were all significant at stage III and PMR was significant at stage IV. Only FMR was significant at stages I, II, and III. Kaplan-Meier survival curves are shown in [Fig. 5](#F5){ref-type="fig"}. The comparisons between BGT and GC and their stages were shown in [Fig. 1](#F1){ref-type="fig"} and the comparisons were significant in BGT vs. GC, I vs. II, I vs. III, I vs. IV, II vs. III, and II vs. IV.

###### Univariate analysis of factors for overall survival at different stages

![](jgc-18-368-i004)

  Factors      P-value                     
  ------------ --------- ------- --------- -------
  Fibrinogen   0.053     0.072   \<0.001   0.932
  FM           0.700     0.247   \<0.001   0.145
  PFM          0.502     0.545   0.001     0.695
  PF           0.186     0.130   0.022     0.846
  PFMR         0.766     0.121   0.253     0.069
  PM           0.787     0.759   0.371     0.958
  Platelet     0.888     0.272   0.448     0.500
  PMR          0.864     0.766   0.861     0.044
  FMR          0.010     0.036   0.018     0.145

FM = fibrinogen\*mean platelet volume; PFM = platelet\*fibrinogen\*mean platelet volume; PF = platelet\*fibrinogen; PFMR = (platelet\*fibrinogen) to mean platelet volume ratio; PM = platelet\*mean platelet volume; PMR = platelet to mean platelet volume ratio; FMR = fibrinogen to mean platelet volume ratio.

![Kaplan-Meier curves for overall survival based on FMR in different stages.\
FMR = fibrinogen to mean platelet volume ratio.](jgc-18-368-g005){#F5}

DISCUSSION
==========

In this study, we found that plasma levels of fibrinogen and platelets were significantly different at various stages and played important influence on prognosis, and this corroborated with previous reports \[[@B6][@B10]\]. Fibrinogen and platelets had crucial effect on the tumorigenesis, tumor progression, and prognosis. In our previous study, we had found that platelet level was closely associated with tumor-induced systemic inflammatory response (SIR) and prognosis of patients with advanced GC \[[@B11]\]. As a main indicator of platelet activation status, MPV has also been reported to be associated with prognosis of malignant diseases \[[@B12][@B13]\]. Therefore, it is essential to combine fibrinogen, platelet, and MPV together to reveal their combined prognostic significance. This investigation was the first successful attempt to appraise the prognosis of patients with GC based on so many indicators obtained by evaluation of fibrinogen, platelet, and MPV levels.

As a major acute reactive phase protein produced by liver, fibrinogen levels increase in the event of malignances or SIR \[[@B14]\], and its level would decrease after surgery and increase again at the time of recurrence \[[@B10]\]. The hyperfibrinogenemia was also reported to affect prognosis in many other malignancies, such as non-small-cell lung cancer \[[@B15]\], esophageal cancer \[[@B16]\], and breast cancer \[[@B17]\]. Fibrinogen promoted lymph node metastasis by interacting with IL-6 and platelets \[[@B18]\]. Mikami et al. \[[@B19]\] reported that platelets can promote the proliferation of gastric cancer cells, which, in turn, can be inhibited by antiplatelet antibodies, meanwhile mir-4670-5p might be involved in this process. Goel et al.\'s \[[@B20]\] experiments also showed that the degree of aspirin-inhibited colon cancer cells was dependent on the mismatch repair (MMR) status. Tumor cells could release high-mobility group box1 protein, and when they escape from the primary tumor, could hang together with fibrinogen and platelets and cluster around to dodge the innate immune systems, especially NK cells, and then, the tumor cells could reside in the vasculature of distant organ \[[@B21][@B22][@B23]\]. The level of MPV, an intimation of platelet size, reflected the activity of the platelets, and the increase in MPV was reported in myocardial infarction and cancers \[[@B24][@B25]\]. But in our study, we found that the MPV was significantly higher in BGT than that in GC and it increased further along with cancer progression. The exact mechanisms of how fibrinogen and platelets promote tumor progression were still controversial.

In the univariate analysis, fibrinogen, platelet, FM, PFM, FMR, PF, PFMR, PM, and PMR were all significant prognostic factors. When incorporated into Cox multivariate analysis, fibrinogen, PFMR, FM, PMR, and FMR all showed prognostic abilities. This may indicate that fibrinogen, platelet, and MPV can be used in combination as indicators of prognosis. But when we divided these patients according to the AJCC TNM stage, FMR showed prognostic ability only in stages I, II, and III; PMR showed prognostic ability only in stage IV; and fibrinogen, FM, PFM, and PF showed prognostic ability only in stage III. This indicated that FMR may be a superior biomarker for predicting survival of patients with GC. In addition, although fibrinogen and platelet facilitated infiltration and migration of tumor cells, we speculated that whether distant metastasis would develop didn\'t depend on the level of fibrinogen and platelet. These indicators may be more suitable to predict survival in non-metastasis GC patients.

The current study has some unavoidable constraints. First, it is a single-center and retrospective research with some uncertain bias. Secondly, the effect of chemotherapy on survival and the relationships between chemotherapy and these biomarkers were not evaluated in this research. However, within these limitations, our findings still showed the prognostic significance of these biomarkers. Although the principle may still be controversial, with their merits of convenience and attractive price without any additional injuries, these biomarkers should be included in prognostic risk stratification models and clinical applications.

In conclusion, elevated levels of fibrinogen and platelets are associated with advanced stages and poor prognosis, and fibrinogen, platelet, and MPV can be combined together for predicting survival of patients with GC. Meanwhile, fibrinogen and FMR can be considered as independent risk factors for overall survival in non-metastatic GC. This will help clinicians to formulate therapeutic strategies and provide better cure to the patients.
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